Pharmaceuticals, Biotechnology and Life Sciences
Japan’s Ministry of Health, Labour and Welfare has approved GSK’s Arexvy, the country’s first respiratory syncytial virus (RSV) vaccine for older adults.
MC2 Therapeutics has acquired option rights from Regranion, LLC to exclusively license Regranion’s RGRN-305 for the treatment of all human…
As part of a collaborative working agreement between United Lincolnshire Hospitals NHS Trust and pharmaceutical company Boehringer Ingelheim, a new cardio-diabetic outpatient service has been launched to help reduce recurring heart attacks in people with diabetes.
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial.
The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Adtralza tralokinumab in a new pre-filled pen, following the European Commission (EU) decision on the 1st of September 2023. The pre-filled pen will be available in the UK for tralokinumab patients from early 2024.
The U.S. Food and Drug Administration today approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS). Approval of Tyruko by the European Medicines Agency is also expected imminently.
BridgeBio Pharma announced today that detailed Phase 3 results from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or…
AiCuris Anti-infective Cures AG has received milestone payments in the amount of EUR €30 million from its licensing partner MSD (Merck) after the U.S. FDA’s approval for first-in-class antiviral agent PREVYMIS® in a new indication – the prophylaxis of CMV disease after kidney transplant in Donor CMV-seropositive/Recipient CMV-seronegative patients.
Rentschler Biopharma, a leading global contract development and manufacturing organisation (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), announces a collaboration with the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of cell and gene therapies, and Refeyn Ltd., the Oxford based mass photometry pioneer.
Redx has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for the potential treatment of Idiopathic Pulmonary Fibrosis (IPF) for Zelasudil, which is currently in a Phase 2a clinical study for IPF, with topline data expected in Q1 2024.